Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injectio...
April 16 2015 - 12:53PM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced that it will conduct a conference
call to discuss the approval of Glatopa™ (glatiramer acetate
injection, formerly M356) 20mg/mL, the first substitutable generic
for COPAXONE®.
Management will host a conference call today at 1:30 pm ET. To
access the call, please dial (877) 224-9084 (domestic) or (720)
545-0022 (international) prior to the scheduled conference call
time and provide the access code 30313041. A replay of the call
will be available approximately two hours after the conclusion of
the call and will be accessible through July 16, 2014. To access
the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406
(international) and provide the access code 30313041.
The audio webcast of the presentation will be available live on
the "Investors" section of the company's website located at
www.momentapharma.com. An archived version of the webcast will be
posted on the Momenta website approximately two hours after the
call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing
in the detailed structural analysis of complex drugs and is
headquartered in Cambridge, MA. Momenta is applying its
technology to the development of generic versions of complex drugs,
biosimilar and potentially interchangeable biologics, and to the
discovery and development of novel therapeutics for oncology and
autoimmune indications.
To receive additional information about Momenta, please visit
the website at www.momentapharma.com, which does not form a
part of this press release.
Our logo, trademarks, and service marks are the property of
Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or
service marks are property of their respective owners.
Copaxone is a registered trademark of Teva Pharmaceuticals.
Glatopa is a trademark of Novartis AG.
CONTACT: Momenta Pharmaceuticals, Inc.
ir@momentapharma.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024